GLP-1/GIP receptor (dual) drugs for Type 2 Diabetes
9 tracked GLP-1/GIP receptor (dual) drugs in the Type 2 Diabetes race. The class explanation lives on the GLP-1/GIP receptor (dual) page; the full indication pipeline across every mechanism is on the Type 2 Diabetes page.
1 approved / phase 47 Phase 31 Phase 2
Head-to-head evidence: BGM0504 vs NNC0519-0130 · BGM0504 vs Tirzepatide (Mounjaro) · BGM0504 vs ribupatide · HDM1005 vs NNC0519-0130 · HDM1005 vs Tirzepatide (Mounjaro) · HDM1005 vs ribupatide